Core Viewpoint - BlissBio Inc. is advancing its lead candidate BB-1701, a HER2-targeted ADC, aimed at addressing unmet needs in cancer treatment, particularly for patients with HER2-positive breast cancer and other HER2-expressing cancers [1][2][4]. Company Overview - Founded in 2017, BlissBio Inc. is a clinical-stage biopharmaceutical company focused on developing next-generation antibody-drug conjugates (ADCs) [1][2]. - The company has submitted its IPO prospectus to the Hong Kong Stock Exchange, with plans for a main board listing [1]. Product Pipeline - BlissBio's ADC pipeline includes four clinical-stage candidates: - BB-1701 (HER2-targeted ADC for breast cancer and other cancers) - BB-1705 (EGFR-targeted ADC) - BB-1712 (anti-B7-H3 ADC) - BB-1709 (CD73 ADC) - All pipeline assets have full global rights [2][4]. BB-1701 Details - BB-1701 is the leading clinical candidate for treating patients previously treated with TOP1-i ADCs, utilizing the established drug Ailubulin as its payload [4]. - The drug has shown promising efficacy and manageable safety in ongoing Phase II studies across the US, Europe, Japan, and China [4]. - The company is actively exploring the expansion of BB-1701's indications and potential combinations with other therapies, such as immunotherapy and targeted treatments [4]. Funding and Use of Proceeds - BlissBio has secured investments from notable institutions, including Hillhouse Capital and Cormorant Asset Management [5]. - The funds raised from the IPO will primarily support the development and commercialization of BB-1701, as well as other key products and pipeline assets [5].

Core Viewpoint - BlissBio Inc. (百力司康) has submitted a listing application to the Hong Kong Stock Exchange, with Goldman Sachs, Huatai International, and Jianyin International acting as joint sponsors [1] Company Overview - BlissBio Inc. is a clinical-stage biopharmaceutical company focused on developing next-generation antibody-drug conjugates (ADCs) to address significant unmet needs in cancer treatment. The company has a pipeline consisting of four clinical-stage ADC candidates [4] - The core product, BB-1701, is a HER2-targeted ADC candidate primarily aimed at breast cancer (BC), non-small cell lung cancer (NSCLC), and potentially other HER2-expressing cancers. The company also has three other ADC candidates in clinical stages: BB-1705 (EGFR ADC), BB-1712 (anti-B7-H3 ADC), and BB-1709 (CD73 ADC) [4] Product Development - BB-1701 is the leading HER2 ADC candidate for patients previously treated with TOP1-i ADC globally. It utilizes Ailubulin as an effective payload, leveraging its multifaceted mechanism of action and differentiated resistance mechanisms. The drug has shown promising efficacy and manageable safety in ongoing Phase II studies in the US, Europe, Japan, and China, with only three cases of ILD reported among 260 patients [5] Manufacturing and Quality Control - The company possesses essential capabilities in chemistry, manufacturing, and control (CMC) development, providing high-quality, efficient, and cost-effective solutions for antibody development and ADC construction. The company has demonstrated the ability to advance projects from preclinical candidates to Investigational New Drug (IND) status in 14 months, significantly faster than the industry average of 18 months [6] Financial Performance - For the fiscal years 2023 and 2024, BlissBio Inc. reported revenues of approximately 180.2 million RMB and 22.6 million RMB, respectively. The company incurred losses of approximately 206.4 million RMB in 2023 and 556.6 million RMB in 2024 [6][7]

Group 1 - As of June 20, 2025, there have been 32 new listings in the Hong Kong stock market, raising a total net amount of HKD 77.969 billion, significantly higher than the total of HKD 13.464 billion raised in the first half of 2024 [1] - The number of A-share companies listing in Hong Kong has increased, with 6 A+H share companies successfully listing this year, reflecting strong demand from investors for quality A-share listings [1] - The 6 A+H share companies had a strong debut in the Hong Kong market, with most experiencing double-digit percentage increases, and Chifeng Jilong Gold Mining Co. seeing a cumulative increase of 117.20% [1] Group 2 - The A-share company Sanhua Intelligent Controls is set to list in Hong Kong on June 23, 2025, with an issue price of HKD 22.53, aiming to raise HKD 0.811 billion for product development and global expansion [2] Group 3 - Traditional consumer stocks have underperformed, while new consumption stocks have thrived, with companies like Haitian Flavoring and Food Co. and Shubao International seeing significant stock price increases [3] - New consumption stocks such as milk tea brands have shown remarkable performance, with shares of Misha Group and Hu Shang Ayi increasing by 153.83% and 20.67% respectively since their listings [3] Group 4 - The trend of collectible toy stocks has also emerged, with Pop Mart International seeing a cumulative stock price increase of over 100% [4] - The toy company Blok has attracted significant interest, with its Hong Kong public offering being oversubscribed by 6,000 times [4] Group 5 - Five unprofitable biotech companies have listed in Hong Kong this year, with Mirxes and Brainstorm Aurora showing strong stock performance since their listings, with increases of 48.71% and 113.66% respectively [5][6] - The focus on "hard tech + medical" sectors has led to high valuations for these unprofitable biotech firms, despite their current losses [6] Group 6 - At least 10 more companies are expected to list in the remaining days of June, including traditional consumer stocks and unprofitable biotech firms, with their performance yet to be determined [7][8]

Group 1 - The core agreement involves a strategic collaboration between Xiansheng Pharmaceutical's subsidiary Xiansheng Zaiming and US biopharmaceutical company NextCure for the development and commercialization of the antibody-drug conjugate (ADC) SIM0505, targeting CDH6, with a total potential payment of up to $745 million [2][5] - SIM0505 is positioned as a novel ADC with a proprietary TOPO inhibitor payload, showing strong anti-tumor effects in preclinical studies and a high systemic clearance rate, indicating potential for an expanded therapeutic window [3][4] - The collaboration includes a unique bidirectional technology partnership, allowing NextCure to utilize Xiansheng Zaiming's proprietary ADC linker and TOPO inhibitor payload for its own ADC development, while Xiansheng Zaiming retains rights for this new ADC in Greater China [4] Group 2 - The $745 million deal marks a significant milestone in Xiansheng Pharmaceutical's strategy for international expansion and highlights the successful global outreach of Chinese innovative drugs through business development (BD) models [5] - The collaboration underscores the international recognition of Chinese pharmaceutical companies' capabilities in cutting-edge technologies like ADCs, with Xiansheng Zaiming's proprietary payload being noted for its potential superior safety and efficacy compared to other topoisomerase inhibitors [5][6] - In recent years, Xiansheng Pharmaceutical has secured over $2.3 billion in potential transaction value through three overseas licensing agreements for self-developed innovative drugs, indicating a proactive shift towards globalizing Chinese original drugs [5]

Investment Rating - The investment rating for the pharmaceutical and biotechnology industry is "Positive" (maintained) [2] Core Insights - SYS6010, a broad-spectrum anti-tumor drug, has shown excellent early data for NSCLC (non-small cell lung cancer) and is currently in the registration phase of clinical trials in China [6][28] - The pharmaceutical and biotechnology sector has outperformed the CSI 300 index, with a 1.4% increase in the second week of June 2025, ranking fifth among 31 sub-industries [30][34] Summary by Sections SYS6010 Development - SYS6010 is an EGFR antibody-drug conjugate (ADC) developed by Shiyao Group, targeting multiple cancers including NSCLC, breast cancer, and colorectal cancer [14][19] - As of June 2025, SYS6010 has entered the registration phase of clinical trials in China for NSCLC and has received multiple designations from the FDA and NMPA [6][28] - SYS6010 has demonstrated a median progression-free survival (mPFS) of 7.6 months in patients previously treated with EGFR TKI and platinum-based chemotherapy [28] Market Performance - The pharmaceutical and biotechnology sector saw a 1.4% increase in the second week of June 2025, outperforming the CSI 300 index by 1.66 percentage points [30][34] - The medical research outsourcing sub-sector experienced the highest growth at 4.76%, while the vaccine sector faced the largest decline at 3.34% [34] Clinical Trial Insights - SYS6010 is the first EGFR ADC to enter the registration phase for lung cancer globally, with promising early data presented at the 2025 AACR conference [28] - The drug has been recognized for its potential in treating EGFR TKI-resistant NSCLC patients, addressing a significant unmet medical need in this patient population [25][28]

Core Insights - Minghui Pharmaceutical is rapidly emerging in the biotech sector, showcasing significant advancements in its drug pipeline and commercial potential [1][2][16] Group 1: Recent Developments - On May 9, Minghui Pharmaceutical licensed MHB088C (B7-H3 ADC) rights in Greater China to Qilu Pharmaceutical, potentially generating a total transaction value of up to 1.345 billion RMB, including an upfront payment of 280 million RMB [1] - The company initiated a Phase III clinical trial for IGF-1R antibody MHB018A for the treatment of thyroid eye disease on May 25 [1] - The application for the market approval of the topical JAK inhibitor Itolizumab ointment (MH004) for atopic dermatitis was accepted by the National Medical Products Administration on May 31 [1] Group 2: Company Background - Established in 2018, Minghui Pharmaceutical raised 80 million RMB in its Pre-A round and over 70 million USD in its second round of financing in 2020 [2] - The founder, Dr. Cao Guoqing, has extensive experience in the pharmaceutical industry, having worked at Eli Lilly and served as Vice President at Hengrui Medicine before founding Minghui [1][2] Group 3: Drug Pipeline and Market Position - Minghui has developed a diverse pipeline including monoclonal antibodies, bispecific antibodies, ADCs, and ointments, with notable products like MHB088C, MHB039A, and MH004 [2][6] - MHB088C, developed using the proprietary SuperTopoi™ ADC platform, has shown promising clinical results with an overall response rate (ORR) of 61.3% in small cell lung cancer patients [4][5] - The company is positioned well in the ADC market, with no approved B7-H3 ADC products globally and three candidates, including MHB088C, in Phase III trials [2][4] Group 4: Commercialization Potential - MH004 is expected to be the first commercial product for Minghui, with a projected approval in 2026, addressing a significant market need for atopic dermatitis treatment in China, where over 70 million patients are affected [5][6] - The company is also advancing MHB018A for thyroid eye disease, with a Phase III trial initiated to address the unmet clinical needs in this area [6][7] Group 5: Business Development Opportunities - Minghui's PD-L1/VEGF bispecific antibody MHB039A is currently in clinical trials and has potential for business development (BD) partnerships, reflecting the growing market interest in this therapeutic area [10][12] - The company is exploring additional BD opportunities with its ADC products, including MHB009C and MHB042C, which are in early clinical stages and have shown promise in the competitive landscape [10][15] Group 6: Strategic Vision - Minghui Pharmaceutical aims to convert its research value into commercial success through strategic BD transactions, supported by a differentiated R&D strategy that fosters a multi-dimensional innovation engine [16]

Investment Rating - The investment rating for the industry is "Positive" and is maintained [9] Core Insights - CEACAM5 is a member of the immunoglobulin superfamily adhesion molecules, highly expressed in various malignancies such as colorectal cancer, gastrointestinal cancer, and lung cancer, playing a significant role in tumor occurrence, invasion, and metastasis [2][6][18] - With the first clinical trial of SAR408701 by Sanofi entering Phase III, CEACAM5 ADC has become a popular development direction for targeted therapy drugs [2][28] - Currently, there are 8 CEACAM5-targeted ADCs in development globally, with 6 having entered clinical stages, showcasing a trend of diverse technological pathways and distinctive mechanisms among major pharmaceutical companies [2][8] Summary by Sections CEACAM5 as a Target - CEACAM5 is recognized as a high-expression tumor target, with its drug development potential accelerating due to the emergence of various therapeutic approaches, including ADCs, monoclonal antibodies, bispecific antibodies, CAR-T cell therapies, and therapeutic vaccines [6][28] CEACAM5 ADC Development - The heat around CEACAM5 ADC is rising, with the design of effective connections being key to overcoming challenges related to its weak internalization capacity [7][32] - The development focus is shifting towards optimizing linkers and payload systems to enhance stability and ensure precise release in the tumor microenvironment [7][32] Competitive Landscape - Major pharmaceutical companies are actively positioning themselves in the CEACAM5 ADC space, with notable developments from Sanofi, Merck, Innovent, and BeiGene, each showcasing unique design strategies and therapeutic potentials [8][50][58][61] - Sanofi's SAR408701, despite facing setbacks, continues to explore its potential in other cancer types, while Merck's M9140 is the first to utilize a topoisomerase I inhibitor in this context [8][50] Investment Perspective - The report suggests that the ongoing innovation in drug development, particularly in the context of CEACAM5-targeted therapies, presents significant investment opportunities, especially for companies with strong cash flows and innovative capabilities [64]

Investment Rating - The report initiates coverage with an OUTPERFORM rating, targeting a price of HK$269.70 from a current price of HK$214.40 [1]. Core Insights - The company is positioned as a leading player in the ADC industry, with a robust pipeline of 12 self-developed ADC candidates, 7 of which are in clinical development, and aims to become China's equivalent of Daiichi Sankyo [3][8]. - The company has established significant global partnerships, including collaborations with BioNTech and others, with a total transaction value exceeding US$6 billion, enhancing its competitive edge in the ADC market [4][22]. - The management team is highly internationalized and experienced, focusing on unmet clinical needs and demonstrating strong operational efficiency [6][19]. Financial Projections - Revenue projections for FY25-27 are estimated at RMB 9.75 billion, RMB 11.7 billion, and RMB 16.1 billion respectively, with net profits expected to be negative in the initial years but improving towards FY27 [7]. - The company utilizes a risk-adjusted discounted cash flow (DCF) model for valuation, with a WACC of 10.0% and a perpetual growth rate of 3.5% [7]. Pipeline and Development - The company has a diverse ADC pipeline targeting various cancers, including DB-1303 (HER2 ADC) and DB-1311 (B7-H3 ADC), with significant clinical progress and potential market opportunities [8][31]. - DB-1303 is expected to submit a New Drug Application (NDA) to the FDA in 2025, with a peak sales potential of US$2 billion, while DB-1311 is also advancing in clinical trials with promising data [31][32]. Strategic Collaborations - The company has formed strategic alliances with major pharmaceutical companies, enhancing its research capabilities and market reach, including a notable partnership with BioNTech for ADC development [22][26]. - The collaborations are expected to accelerate the development of ADC therapies and maximize their global value [24][26]. Management and Expertise - The management team includes industry veterans with extensive experience in drug development and investment, which supports the company's strategic direction and operational efficiency [19][21]. - The company benefits from a scientific advisory board composed of renowned ADC experts, further strengthening its research and development capabilities [20].

Core Viewpoint - The enthusiasm of mainland companies for listing on the Hong Kong stock market has surged, with 248 out of 450 companies applying for IPOs, indicating strong interest in the market [1] Group 1: IPO Trends and Market Dynamics - The Hong Kong market has seen a record IPO fundraising amount exceeding HKD 56 billion since March 2021, with a total fundraising scale of HKD 77.4 billion this year, nearing last year's total [1] - The increasing number of listing applications has led to regulatory review congestion, with an average filing time of 5-6 months, resulting in many companies needing to submit applications multiple times [1][2] - The trend of "secondary submissions" is widely accepted in the market and does not significantly hinder the final listing process [1] Group 2: Company Overview - Weili Zhibo - Weili Zhibo has completed 8 rounds of financing, raising a total of CNY 1.084 billion, attracting notable investment from firms like Enran Venture Capital and Shenzhen Capital Group [2] - The company focuses on innovative therapies for cancer and autoimmune diseases, with a diverse pipeline that includes 14 candidate drugs [2][5] - Weili Zhibo has established three core technology platforms: ADC, IO 2.0, and TCE, enhancing its competitive edge in the biopharmaceutical field [3][5] Group 3: Product Pipeline and Clinical Development - The core product LBL-024 is the first targeted 4-1BB therapy in the registration clinical stage globally, with significant market potential in treating various solid tumors [5][7] - LBL-034, a TCE targeting GPRC5D, is in I/II phase clinical trials in China and is positioned to be the first domestic TCE therapy targeting GPRC5D [8] - The ADC product LBL-058 has shown strong efficacy in preclinical models, indicating potential in treating DLL3-positive small cell lung cancer [9] Group 4: Market Potential and Future Outlook - The global market for 4-1BB antibody drugs is projected to reach USD 2.9 billion by 2030, with a CAGR of 284.9% from 2026 to 2030, driven by a large patient population across various cancer types [5] - The ongoing clinical studies for LBL-024 aim to expand its indications into high-incidence cancer areas, further broadening its market reach [6][7] - The comprehensive innovation capabilities of Weili Zhibo across its technology platforms reflect the core driving force behind the transformation and upgrading of the Chinese pharmaceutical industry [9][10]

Core Viewpoint - The Chinese biopharmaceutical industry, represented by Baotai Biopharmaceutical Co., Ltd., is enhancing its international competitiveness through innovation amidst a restructuring global medical technology landscape [2]. Group 1: Company Overview - Baotai, established in 2003, focuses on the research and development of innovative drugs and biosimilars, targeting diseases such as cancer and autoimmune disorders [3]. - The company has shown steady revenue growth from 455 million yuan in 2022 to 743 million yuan in 2024, with a compound annual growth rate of 27.8% [3]. Group 2: Product Portfolio and Globalization - Baotai has several marketed products, including Adalimumab injection and Bevacizumab injection, contributing significantly to its revenue [3]. - The company has established commercial partnerships for six products across over 92 countries, with its products receiving regulatory approvals from the FDA and EMA [4]. - Baotai aims to have four products launched globally by 2027, indicating a strong pipeline for future growth [4]. Group 3: Research and Development Strategy - R&D expenditures from 2022 to 2024 were 616 million yuan, 769 million yuan, and 778 million yuan, respectively, reflecting a commitment to maintaining competitive positioning through innovation [6]. - The company is focusing on developing next-generation antibody-drug conjugates (ADCs) and bispecific antibodies in oncology and autoimmune fields [6]. - Baotai emphasizes a dual-track strategy of innovative drugs and biosimilars to drive long-term growth [6]. Group 4: Technological Integration and Future Outlook - Baotai's BAT2206 is expected to receive FDA approval in May 2025, with other products also progressing through regulatory pathways [7]. - The company is integrating AI technology into various stages of drug development, aiming to make it a foundational aspect of R&D and production [7]. - Baotai's supply chain remains resilient against global trade tensions, primarily sourcing raw materials domestically [8].